Compare FSBC & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FSBC | PLRX |
|---|---|---|
| Founded | 2002 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 73.7M |
| IPO Year | 2021 | 2020 |
| Metric | FSBC | PLRX |
|---|---|---|
| Price | $46.19 | $1.17 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 5 | 4 |
| Target Price | ★ $41.90 | $2.67 |
| AVG Volume (30 Days) | 133.7K | ★ 437.8K |
| Earning Date | 04-27-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.47% | N/A |
| EPS Growth | 28.32 | ★ 29.97 |
| EPS | ★ 1.78 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $30.25 | N/A |
| Revenue Next Year | $12.30 | N/A |
| P/E Ratio | $25.79 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $30.68 | $1.02 |
| 52 Week High | $50.26 | $1.95 |
| Indicator | FSBC | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 51.34 | 55.13 |
| Support Level | $44.68 | $1.12 |
| Resistance Level | $47.57 | $1.26 |
| Average True Range (ATR) | 0.94 | 0.04 |
| MACD | 0.14 | 0.00 |
| Stochastic Oscillator | 70.04 | 57.87 |
Five Star Bancorp is a bank holding company that operates in California through its subsidiary, a state-chartered non-member bank. The company provides a broad range of banking products and services to small and medium-sized businesses, professionals, and individuals. It offers loan products like commercial real estate loans, commercial loans, commercial land and construction loans, and farmland loans, and offers deposit products like checking accounts, savings accounts, money market accounts, and term certificate accounts. The group has one reportable operating segment: Banking.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.